JOUNCE THERAPEUTICS INC's ticker is JNCE and the CUSIP is 481116101. A total of 131 filers reported holding JOUNCE THERAPEUTICS INC in Q2 2021. The put-call ratio across all filers is 5.36 and the average weighting 0.7%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2022 | $159,000 | -72.3% | 52,462 | -23.7% | 0.00% | – |
| Q4 2021 | $574,000 | +124.2% | 68,776 | +100.0% | 0.00% | – |
| Q3 2021 | $256,000 | -52.3% | 34,388 | -56.4% | 0.00% | – |
| Q2 2021 | $537,000 | +219.6% | 78,923 | +223.9% | 0.00% | – |
| Q2 2020 | $168,000 | -43.6% | 24,367 | -28.5% | 0.00% | – |
| Q4 2019 | $298,000 | -46.5% | 34,068 | -79.6% | 0.00% | -100.0% |
| Q3 2019 | $557,000 | -15.6% | 167,038 | +25.2% | 0.00% | 0.0% |
| Q2 2019 | $660,000 | -38.8% | 133,443 | -23.2% | 0.00% | 0.0% |
| Q1 2019 | $1,078,000 | +241.1% | 173,808 | +85.3% | 0.00% | – |
| Q4 2018 | $316,000 | -29.8% | 93,776 | +35.5% | 0.00% | -100.0% |
| Q3 2018 | $450,000 | -34.8% | 69,204 | +124.1% | 0.00% | 0.0% |
| Q1 2018 | $690,000 | +154.6% | 30,879 | +59.8% | 0.00% | – |
| Q2 2017 | $271,000 | -39.1% | 19,323 | -4.5% | 0.00% | -100.0% |
| Q1 2017 | $445,000 | – | 20,240 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| TRV GP II, LLC | 2,697,829 | $20,045,000 | 88.84% |
| TRV GP III, LLC | 3,048,780 | $22,652,000 | 4.30% |
| Logos Global Management LP | 2,000,000 | $14,860,000 | 1.07% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 208,559 | $1,550,000 | 0.88% |
| PFM Health Sciences, LP | 3,848,822 | $28,597,000 | 0.84% |
| Yorktown Management & Research Co Inc | 113,200 | $841,000 | 0.63% |
| Moloney Securities Asset Management, LLC | 282,250 | $2,097,000 | 0.38% |
| PATHWAY CAPITAL MANAGEMENT, LP | 84,763 | $630,000 | 0.30% |
| Sofinnova Investments, Inc. | 637,347 | $4,735,000 | 0.28% |
| Omega Fund Management, LLC | 275,513 | $2,047,000 | 0.23% |